(Q35144964)

6 August 2017

1 reference

title

Drug-induced movement disorders in children. (English)

1 reference

6 August 2017

1 reference

Robert L Rodnitzky

1

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Seminars in pediatric neurology

6 August 2017

published in

1 reference

6 August 2017

volume

10

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

80-87

1 reference

Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Prescribing of psychotropic drugs to children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Acute dystonia induced by neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Upper airway compromise in acute chlorpromazine ingestion

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Dystonic reactions following neuroleptics: Time Course and proposed mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Predictors of acute dystonia in first-episode psychotic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Cocaine-associated dystonic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Acute dystonic reactions to "street Xanax".

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Neuroleptic malignant syndrome following initiation of clozapine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Neuroleptic malignant syndrome associated with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Risperidone-induced neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Fluoxetine and neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Neuroleptic malignant syndrome and methylphenidate

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Case-control study of neuroleptic malignant syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Incidence and risk factors in neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Neuroleptic malignant syndrome in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Neuroleptic malignant syndrome: two cases without muscle rigidity

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Drug-induced hyperthermia

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Carbamazepine in the treatment of neuroleptic malignant syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Plasmapheresis in neuroleptic malignant syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Selective serotonin reuptake inhibitor-induced serotonin syndrome: review

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

A case of serotonin syndrome caused by venlafaxine and lithium

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Serotonin syndrome: history and risk

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Sertraline intoxication in a child

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

MDMA (ecstasy) and the rave: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Serotonin syndrome complicating migraine pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

1 reference

7 January 2021

Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

The epidemiology of drug-induced akathisia: Part I. Acute akathisia.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Akathisia: a review and case report following paroxetine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Akathisia: a comprehensive review and treatment summary

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Recognition and differential diagnosis of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

In Search of Treatment for Tardive Dyskinesia: Review of the Literature*

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Treatment of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Marked reduction of tardive dyskinesia with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Long-term effects of tetrabenazine in hyperkinetic movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Vitamin E (α-Tocopherol) in the Treatment of Tardive Dyskinesia: A Statistical Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

A treatment for tardive dyskinesia and some other extrapyramidal symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2802%2900013-X

7 January 2021

10.1016/S1071-9091(02)00013-X

Identifiers

DOI

1 reference

6 August 2017

1 reference